Freeline will present a new clinic
LONDON, June 24, 2022 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (FRLN) today announced the upcoming presentation of important new clinical data for its AAVS3-based gene therapy candidate FLT180a to the International Society of Thrombosis and haemostasis (ISTH) Congress to be held in London, July 9-13, 2022. Presentation will provideRead More →